Page 1

Exhibit 99.1 image_1.jpg Spyre Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update Announced positive topline induction data for SPY001 and SPY002 from Part A of the Phase 2 SKYLINE trial ( “ SKYLINE " ) , demonstrating best - in - class efficacy potential and a safety profile consistent with in - class comparators Announced enrollment completion for the Phase 2 SKYWAY basket trial ( " SKYWAY " ) , with all three sub - studies over - enrolling on or ahead of schedule , which we believe reflects significant investigator enthusiasm for new treatment options in these indications Remain on track for 6 proof - of - concept Phase 2 readouts in 2026 , with the rheumatoid arthritis ( " RA " ) sub - study in SKYWAY and the SPY003 Part A data from SKYLINE expected in September and the psoriatic arthritis ( " PsA ” ) and axial spondyloarthritis ( " axSpA " ) sub - studies of SKYWAY expected in the fourth quarter $ 1.1 billion in cash , cash equivalents , and marketable securities as of June 30 , 2026 , with expected runway into the second half of 2029 Waltham , Mass , August 4 , 2026 ( GLOBE NEWSWIRE ) - Spyre Therapeutics , Inc. ( " Spyre " or the " Company " ) ( NASDAQ : SYRE ) , a clinical - stage biotechnology company committed to developing next - generation therapies that elevate the standard in immunology by delivering more complete disease control , greater durability , and a simpler treatment experience for patients , today announced its second quarter 2026 financial results and provided program and corporate updates . " Following encouraging Phase 2 results from both SPY001 and SPY002 , as well as competitor results validating the promise of combination therapy , the case for our approach in IBD has strengthened considerably . We believe our three investigational combinations have the potential to deliver efficacy , safety , and convenience beyond what is achievable with today's therapies , " said Cameron Turtle , DPhil , Chief Executive Officer of Spyre . “ Beyond IBD , we are approaching a pivotal milestone with placebo - controlled Phase 2 proof - of - concept data for SPY072 , an anti - TL1A monotherapy , in rheumatoid arthritis expected next month , representing a key opportunity to demonstrate the broader utility of this mechanism . If successful , we look forward to initiating pivotal development of SPY072 next year , while also exploring combination approaches outside IBD . " Development Pipeline Overview and Update The Company is developing next - generation therapies that elevate the standard in immunology , with an initial focus in inflammatory bowel disease ( " IBD " ) and rheumatic diseases , including RA , PsA , and axSpA . IBD is a chronic condition characterized by inflammation within the gastrointestinal tract , including two main disorders : ulcerative colitis ( " UC " ) and Crohn's disease ( " CD " ) . In the United States , it is estimated that approximately 2.4 million individuals are diagnosed with IBD . RA , PsA , and axSpA are chronic inflammatory autoimmune conditions primarily characterized by pain , stiffness , and swelling of the joints , as well as impacts on the spine and skin . Together , these rheumatic conditions affect more than three million individuals in the United States . Existing